Plasma cytokines can help to identify the development of severe acute pancreatitis on admission

Li-Hui Deng, Cheng Hu, Wen-Hao Cai, Wei-Wei Chen, Xiao-Xin Zhang, Na Shi, Wei Huang, Yun Ma, Tao Jin, Zi-Qi Lin, Kun Jiang, Jia Guo, Xiao-Nan Yang, Qing Xia, Li-Hui Deng, Cheng Hu, Wen-Hao Cai, Wei-Wei Chen, Xiao-Xin Zhang, Na Shi, Wei Huang, Yun Ma, Tao Jin, Zi-Qi Lin, Kun Jiang, Jia Guo, Xiao-Nan Yang, Qing Xia

Abstract

Severe acute pancreatitis (AP) is associated with high morbidity and mortality. Early severity stratification remains a challenging issue to overcome to improve outcomes. We aim to find novel plasma cytokines for the early identification of severe AP according to the revised Atlanta criteria.In this prospective observational study, 30 cytokines, screened semiquantitatively with a human multicytokine array, were submitted to quantitative determination using either microparticle-based multiplex immunoassays analyzed on a Luminex 100 platform or enzyme-linked immunosorbent assay kits. The cytokine profiles of patients and the discriminative value of cytokines for severe AP were analyzed.Plasma samples of 70 patients with AP (20 mild, 30 moderately severe, and 20 severe) were selected in this study if they were admitted within 48 hours of the onset of symptoms. Plasma from healthy volunteers was collected as the healthy control. Growth differentiation factor-15 (GDF-15) and pentraxin 3 (PTX3) on admission were independent prognostic markers for the development of severe AP and had higher discriminative powers than conventional markers (GDF-15 vs hematocrit, P = .003; GDF-15 vs C-reactive protein, P = .037; GDF-15 vs creatinine, P = .048; GDF-15 vs Acute Physiology and Chronic Health Evaluation II, P = .007; PTX3 vs hematocrit, P = .006; PTX3 vs C-reactive protein, P = .047; PTX3 vs Acute Physiology and Chronic Health Evaluation II, P = .011; PTX3 vs Bedside Index for Severity in Acute Pancreatitis, P = .048).Plasma GDF-15 and PTX3 can help to identify the development of severe AP on admission. Future work should validate their accuracy in a larger, multicenter patient cohort.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
The differential expression of 30 cytokines associated with AP screened out by the Proteome Profiler Human XL Cytokine Array kit. AP = acute pancreatitis.
Figure 2
Figure 2
The ROC curves for the comparisons of growth differentiation factor-15 (GDF-15), pentraxin 3 (PTX3), and conventional markers on admission for the identification of severe acute pancreatitis. (A) GDF-15 and PTX3 versus single parameters. (B) GDF-15 and PTX3 versus scoring systems. ROC curve = receiver-operating characteristic curve.

References

    1. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet 2015;32:81–92.
    1. Wu BU, Banks PA. Clinical management of patients with acute pancreatitis. Gastroenterology 2013;144:1272–81.
    1. Forsmark CE, Vege SS, Wilcox CM. Acute Pancreatitis. N Engl J Med 2016;375:1972–81.
    1. Tenner S, Baillie J, DeWitt J, et al. American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol 2013;108:1400–15. 1416.
    1. Huang W, Altaf K, Jin T, et al. Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: a meta-analysis. World J Gastroenterol 2013;19:4607–15.
    1. Jin T, Huang W, Jiang K, et al. Urinary trypsinogen-2 for diagnosing acute pancreatitis:a meta-analysis. Hepatobiliary Pancreat Dis Int 2013;12:355–62.
    1. Deng L, Wang L, Yong F, et al. Prediction of the severity of acute pancreatitis on admission by carboxypeptidase-B activation peptide: a systematic review and meta-analysis. Clin Biochem 2015;48:740–6.
    1. Staubli SM, Oertli D, Nebiker CA. Laboratory markers predicting severity of acute pancreatitis. Crit Rev Clin Lab Sci 2015;52:273–83.
    1. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002;9:401–10.
    1. Sah RP, Dawra RK, Saluja AK. New insights into the pathogenesis of pancreatitis. Curr Opin Gastroenterol 2013;29:523–30.
    1. Singh VK, Wu BU, Bollen TL, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol 2009;7:1247–51.
    1. Zhang J, Niu J, Yang J. Interleukin-6, interleukin-8 and interleukin-10 in estimating the severity of acute pancreatitis: an updated meta-analysis. Hepatogastroenterology 2014;61:215–20.
    1. Brivet FG, Emilie D, Galanaud P. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Crit Care Med 1999;27:749–55.
    1. Chen CC, Wang SS, Lee FY, et al. Proinflammatory cytokines in early assessment of the prognosis of acute pancreatitis. Am J Gastroenterol 1999;94:213–8.
    1. Seideman J, Peritt D. A novel monoclonal antibody screening method using the Luminex-100™ microsphere system. J Immunol Methods 2002;267:165–71.
    1. Dunbar SA. Applications of Luminex® xMAP™ technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006;363:71–82.
    1. Dunbar SA, Zee CAV, Oliver KG, et al. Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP™ system. J Microbiol Meth 2003;53:245–52.
    1. Nieminen A, Maksimow M, Mentula P, et al. Circulating cytokines in predicting development of severe acute pancreatitis. Crit Care 2014;18:R104.
    1. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis, 2012: revision of the Atlanta classification and definitions by international consensus. Gut 2012;62:102–11.
    1. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638–52.
    1. Chen Q, Boire A, Xin J, et al. Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 2016;533:493–8.
    1. Westman J, Papareddy P, Dahlgren MW, et al. Extracellular Histones Induce Chemokine Production in Whole Blood Ex Vivo and Leukocyte Recruitment In Vivo. PLoS Pathog 2015;11:e1005319.
    1. Kittang AO, Sand K, Brenner AK, et al. The systemic profile of soluble immune mediators in patients with myelodysplastic syndromes. Int J Mol Sci 2016;17: doi: 10.3390/ijms17071080.
    1. Trabattoni D, Gnudi F, Ibba SV, et al. Thiazolides elicit anti-viral innate immunity and reduce HIV replication. Sci Rep 2016;6:27148.
    1. Delong ER, Delong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
    1. Guo Q, Li A, Xia Q, et al. The role of organ failure and infection in necrotizing pancreatitis: a prospective study. Ann Surg 2014;259:1201–7.
    1. Chen Y, Tong Z, Li W, et al. Association between severity and the determinant-based classification, Atlanta 2012 and Atlanta 1992, in acute pancreatitis a clinical retrospective study. Medicine 2015;94:e638.
    1. Zhao X, Huang W, Li J, et al. Noninvasive positive-pressure ventilation in acute respiratory distress syndrome in patients with acute pancreatitis: a retrospective cohort study. Pancreas 2016;45:58–63.
    1. Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337–66.
    1. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349–54.
    1. Salio M, Chimenti S, De AN, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008;117:1055–64.
    1. Peri G, Introna M, Corradi D, et al. PTX3: a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636–41.
    1. Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008;28:1–3.
    1. Kusnierzcabala B, Gurdaduda A, Dumnicka P, et al. Plasma pentraxin 3 concentrations in patients with acute pancreatitis. Clin Lab 2013;59:1003–8.
    1. Hromas R, Hufford M, Sutton J, et al. PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997;1354:40–4.
    1. Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998;273:13760–7.
    1. Yokoyama-Kobayashi M, Saeki M, Sekine S, et al. Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J Biochem 1997;122:622–6.
    1. Bootcov MR, Breit SN. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 1997;94:11514–9.
    1. Strelau J, Böttner M, Lingor P, et al. GDF-15/MIC-1 a novel member of the TGF-beta superfamily. J Neural Transm Suppl 2000;60:273–6.
    1. Zimmers TA, Jin X, Hsiao EC, et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005;23:543–8.
    1. Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10:2386–92.
    1. Özkan H, Demirbaş S, Ibiş M, et al. Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases. Pancreatology 2011;11:295–300.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir